GlassScriptPhysician profile
Laura Ward
NPI 1225646870
$2,730.94
in general payments reported to CMS, 2019-2025
25 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 88% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $490 · 2024: $1,050 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.47 | 2023-2025 | |
| Pfizer INC. | $442.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $342.66 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $283.70 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $177.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $146.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $115.58 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $92.73 | 2025 | |
| Axsome Therapeutics, INC. | $85.06 | 2023-2025 | Auvelity, Sunosi |
| Amgen INC. | $78.17 | 2024-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.18 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Shield Therapeutics INC | $67.24 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $57.49 | 2023-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $57.18 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Idorsia Pharmaceuticals US INC | $45.79 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.78 | 2024-2025 | Dexcom G6 Transmitter |
| Aerin Medical INC. | $25.36 | 2025 | |
| Sumitomo Pharma America, INC. | $18.75 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.54 | 2025 | Xifaxan |
| Horizon Therapeutics Plc | $18.46 | 2023 | Krystexxa |
| Aimmune Therapeutics, INC. | $17.09 | 2024 | |
| Hikma Pharmaceuticals USA | $16.81 | 2023 | Ryaltris |
| Xeris Pharmaceuticals, INC. | $16.81 | 2025 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $16.77 | 2024 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.01 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.